- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
COVID-19 Variants and Vaccine Benefits-Risks Balance | ||
| Al- Anbar Medical Journal | ||
| Article 1, Volume 17, Issue 2, 2021, Pages 46-48 PDF (247 K) | ||
| Document Type: Editorial article | ||
| DOI: 10.33091/amj.2021.171068 | ||
| Author | ||
| Abdulsalam Al-Ani .* | ||
| Department of Pathology and Forensic Medicine/Hematology, College of Medicine, University Of Anbar, Anbar, Ira | ||
| Abstract | ||
| Since the emergence of coronavirus disease 2019 (COVID-19), the SARS-CoV-2 virus (the causative agent of the disease) has spread and imposed an enormous health burden worldwide. As of 27 July 2021, almost 200 million people were infected with more than 4 million deaths globally (according to WHO Coronavirus Dashboard, https://covid19.who.int/table). Although many treatment modalities have been used or still under trials all over the world, no specific treatment was found to cure or prevent the disease development. Therefore, immunization was regarded the best choice to prevent the development of the disease or at least reduce morbidity and mortality. Using the concept of herd immunity; that; with a threshold at 60 to 70% of the all population gaining immunity through previous exposure to the virus or by vaccinations; can control a very contagious disease. Owing to COVID-19 serious complications and millions of deaths worldwide with a great impact on the health care system, natural infection is an unsuitable option to reach population protection [1]. | ||
| Keywords | ||
| COVID-19; Variants; Vaccine | ||
| References | ||
|
[1] C. Aschwanden, “Five reasons why COVID herd immunity is probably impossible.,” Nature, pp. 520–522, 2021. doi:10.1038/d41586-021-00728-2.
[2] Zimmer C, Corum J, Wee S-L. Covid-19 Vaccine Tracker. Accessed July 25, 2021. https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
[3] CDC, COVID-19 Science Update released; July 16, 2021. Accessed July 23, 2021. https://www.cdc.gov/library/covid19/07162021_covidupdate.html
[4] CDC, Science Brief: COVID-19 Vaccines and Vaccination. Published July 27, 2021. Accessed July 30, 2021. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-people.html
[5] M. D. Tanriover et al., “Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey,” Lancet, vol. 398, no. 10296, pp. 213–222, 2021. doi:10.1016/ S0140-6736(21)01429-X.
[6] N. Al Kaabi et al., “Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial,” Jama, 2021. doi:10.1001/jama.2021.8565.
[7] J. Lopez Bernal et al., “Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant.,” N Engl J Med, pp. 585–594, 2021. doi: 10.1056/NEJMoa2108891.
[8[ Stowe J, Andrews N, Gower C, Gallagher E, Utsi L, Simmons R, et al. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B. 1.617. 2) variant. Public Health England. 2021. Published June 14, 2021. Accessed July 30, 2021. https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view/479607266
[9] C. M. Brown et al., “Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings—Barnstable County, Massachusetts, July 2021,” Morb. Mortal. Wkly. Rep., vol. 70, no. 31, p. 1059, 2021. doi: 10.15585/mmwr.mm7031e2.
[10] S. M. Bartsch et al., “Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention,” Am. J. Prev. Med., vol. 59, no. 4, pp. 493–503, 2020. doi: 10.1016/j.amepre.2020.06.011.
[11] WHO, What are the side effects of COVID-19 vaccines? Coronavirus disease (COVID-19): Vaccines safety. Published February 19, 2021 updated July 29, 2021. Accessed August 3, 2021. https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines-safety
[12] CDC, Selected Adverse Events Reported after COVI-19 Vaccination. Published August 2, 2021. Accessed August 3, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html
[13] Bussel JB, Connors JM and Cines DB. Thrombosis with thrombocytopenia syndrome (also termed vaccine-induced thrombotic thrombocytopenia. Version 1.5. American Society of Hematology July 9, 2021. Accessed August 5, 2021. https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia.
[14] G. M. Arepally and T. L. Ortel, “Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): What We Know and Don’t Know,” Blood, 2021. doi: 10.1182/blood.2021012152.
[15] Taquet M, et al. Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases. Accessed July 30, 2021. https://osf.io/a9jdq/ | ||
|
Statistics Article View: 1,271 PDF Download: 532 |
||